🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

🧪

Trial Match

Clinical trials test new treatments — sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

🎯 Match trials to me

30 recruiting trials

for HER2 + Breast Cancer

Genetically-informed Therapy for ER+ Breast Cancer Post-CDK4/6 Inhibitor NCT05933395Phase 21 site📍 Lebanon Dartmouth-Hitchcock Medical Center · Tests: Fulvestrant, Neratinib, Alpelisib, Everolimus, Abemaciclib Elacestrant in Patients With ER+ HER2- ESR1-mutated Locally Advanced or Metastatic Breast Cancer NCT07563595n/a3 sites📍 Freiburg im Breisgau📍 Paderborn📍 Ravensburg iOMEDICO AG · Tests: Elacestrant, Standard of care (Investigator Choice) Use of Magtrace Bracketing for Excision of Lesion and Sentinel Lymph Node Localization in Breast Conserving Surgery for Breast Cancer NCT07844473NA1 site📍 Madinah King Faisal Specialist Hospital & Research Center · Tests: Super paramagnetic iron oxide bracketing injection Study Evaluating DNA Double-strand Breaks (DSBs) REpair Factors (POLQ, Shieldin Complex and 53BP1) Expression as Biomarker of PARP Inhibitor Resistance in Patients With Deleterious Germline Mutation in BRCA 1/2 and HER2-negative, Metastatic or Locally Advanced Breast Cancer. NCT05378204NA25 sites📍 Bordeaux📍 Caen📍 Clermont-Ferrand Institut Claudius Regaud · Tests: Main study:, Sub-study: Validation of the Oncoliq Test for the Early Detection of Breast Cancer. NCT07331506n/a1 site📍 Buenos Aires Oncoliq US Inc · Tests: Peripheral blood draw Evaluation of [68Ga]Ga-NOTA-anti-HER2-sdAb PET/CT for Predicting Pathological Complete Response After Neoadjuvant Chemotherapy in HER2 Positive Early Breast Cancer NCT07593976Phase 21 site📍 Rouen Centre Henri Becquerel · Tests: [68Ga]Ga-NOTA-anti-HER2-sdAb Positron Emission Tomography SHR-A1811 Alone or in Combination With Adebrelimab as Neoadjuvant Treatment in HR Positive/HER2 Low Breast Cancer NCT06340230Phase 21 site📍 Shenyang Shengjing Hospital · Tests: SHR-A1811 Injection + Adebrelimab Injection, SHR-A1811 Injection + Adebrelimab Injection, SHR-A1811 Injection Utidelone Versus Docetaxel in HER2-negative Locally Advanced or Metastatic Breast Cancer NCT05430399Phase 32 sites📍 Guangzhou📍 Hunan Sun Yat-sen University · Tests: utidelone, docetaxel Olaparib With Cediranib or AZD6738 for the Treatment of Advanced or Metastatic Germline BRCA Mutated Breast Cancer NCT04090567Phase 21 site📍 Houston M.D. Anderson Cancer Center · Tests: Cediranib, Ceralasertib, Olaparib Step Count and Treatment Response in Neoadjuvant Breast Cancer NCT07162675n/a2 sites📍 Ankara📍 Ankara Ankara Etlik City Hospital · Tests: Huawei Fit 2 Smartwatch ABCSG 61 / TEODOR : Neoadjuvant TrEatment Optimization Driven by Circulating Tumor DNA and endOcrine Responsiveness NCT07084558NA14 sites📍 Vienna📍 Baden📍 Dornbirn Austrian Breast & Colorectal Cancer Study Group · Tests: blood sample for Signatera (TM) test, biopsy for Ki-67 assessment, FFPE tumor sample for Signatera (TM) test (archived) Efficacy of Trastuzumab Deruxtecan in Metastatic Breast Cancer With Different HER2 Expression Patterns NCT06551220n/a26 sites📍 New Haven📍 Boston📍 Fuzhou Sun Yat-sen University · Tests: Trastuzumab Deruxtecan A Study of Abemaciclib and Radiation Therapy in People With Metastatic Breast Cancer NCT06678269Phase 17 sites📍 Basking Ridge📍 Middletown📍 Montvale Memorial Sloan Kettering Cancer Center · Tests: Abemaciclib, Radiation Therapy Efficacy of Supplement Adjuvant Capecitabine in HR+/HER2- Breast Cancer Patients With High Risks NCT05212454Phase 31 site📍 Hanzhou Second Affiliated Hospital, Zhejiang University, School of … · Tests: Capecitabine A Study to Learn About the Study Medicine Called PF-08032562 in People With Advanced or Metastatic Solid Tumors NCT07318805Phase 113 sites📍 Duarte📍 Grand Rapids📍 Long Island City Pfizer · Tests: PF-08032562, Fulvestrant, Cetuximab, Fluorouracil, Oxaliplatin Functional Imaging in Prediction of Response to Abemaciclib for Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer NCT06179303Phase 23 sites📍 St Louis📍 Chapel Hill📍 Seattle University of Washington · Tests: Abemaciclib, Anastrozole, Biospecimen Collection, Computed Tomography, Diagnostic Imaging Testing DATO-BASE: DATOpotamab-deruxtecan for Breast Cancer Brain metAstaSEs NCT06176261Phase 23 sites📍 Miami📍 Boston📍 Durham Nancy Lin, MD · Tests: Datopotamab Deruxtecan IKS014 in Advanced Solid Tumors That Express HER2 NCT05872295Phase 113 sites📍 Newport Beach📍 Boston📍 Nashville Iksuda Therapeutics Ltd. · Tests: IKS014 Analysis of Circulating Tumor DNA (ctDNA) in HER2-low Advanced/Metastatic Breast Cancer NCT06706557n/a1 site📍 Milan European Institute of Oncology A Study Comparing BL-M07D1 With DS-8201 in Patients With HR-Positive, HER2-Low Expressing Recurrent/Metastatic Breast Cancer NCT07678957Phase 21 site📍 Beijing Sichuan Baili Pharmaceutical Co., Ltd. · Tests: BL-M07D1, DS-8201 Asciminib in HER2+ Breast Cancer Brain Metastases NCT07136428Phase 1, Phase 21 site📍 Durham Duke University · Tests: Asciminib and Trastuzumab Study of AVZO-021 in Patients With Advanced Solid Tumors NCT05867251Phase 1, Phase 213 sites📍 New Haven📍 Sarasota📍 Tampa Avenzo Therapeutics, Inc. · Tests: AVZO-021, Palbociclib, Fulvestrant, Letrozole, Ribociclib Trastuzumab Deruxtecan (T-DXd) in Patients Who Have Hormone Receptor-negative and Hormone Receptor-positive HER2-low or HER2 IHC 0 Metastatic Breast Cancer NCT05950945Phase 388 sites📍 Miami Beach📍 Tampa📍 Boston Daiichi Sankyo · Tests: Trastuzumab Deruxtecan Neoadjuvant Camrelizumab and Fluzoparib and Nab-paclitaxel in Early Breast Cancer With HRR Gene Mutation NCT05761470Phase 21 site📍 Guangzhou Ying Lin · Tests: Camrelizumab, Fluzoparib, Nab-paclitaxel HR+/HER2- Advanced or Metastatic Breast Cancer Patients Treated With Sacituzumab Govitecan NCT06236269Phase 210 sites📍 Badalona📍 L'Hospitalet de Llobregat📍 Barcelona SOLTI Breast Cancer Research Group · Tests: Sacituzumab Govitecan A Study to Evaluate the Effectiveness and Safety of Inavolisib in Participants With Endocrine-resistant, PIK3CA-mutated, Hormone Receptor-positive, HER2-negative Locally Advanced or Metastatic Breast Cancer NCT07347600n/a32 sites📍 Xiamen📍 Lanzhou📍 Shijiazhuang Hoffmann-La Roche · Tests: Inavolisib, Palbociclib, Fulvestrant A Study of SKB264 Versus Investigator's Choice of Chemotherapy in Subjects With Unresectable Locally Advanced, Relapsed, or Metastatic HR+/HER2- Breast Cancer Who Have Previously Failed Endocrine Therapy NCT07071337Phase 32 sites📍 Beijing📍 Guangzhou Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. · Tests: SKB264, Nab-paclitaxel, Paclitaxel, Capecitabine Neoadjuvant Pyrotinib-to-pertuzumab in HER2+ eBC NCT07797218Phase 31 site📍 Shanghai Shanghai Jiao Tong University School of Medicine · Tests: Docetaxel, Pyrotinib, Trastuzumab (Herceptin), Pertuzumab Neoadjuvant Endocrine Therapy +/- the PI3K Inhibitor Inavolisib in HER2+, HR+, PIK3CA Mutant Early Breast Cancer NCT05306041Phase 262 sites📍 Essen📍 Augsburg📍 Berlin GBG Forschungs GmbH · Tests: Inavolisib, PHESGO, Endocrine therapy A Trial of Early Detection of Molecular Relapse With Circulating Tumour DNA Tracking and Treatment With Palbociclib Plus Fulvestrant Versus Standard Endocrine Therapy in Patients With ER Positive HER2 Negative Breast Cancer NCT04985266Phase 249 sites📍 Angers📍 Annecy📍 Avignon Royal Marsden NHS Foundation Trust · Tests: Palbociclib 125Mg Tab, Fulvestrant injection, Tamoxifen, Letrozole, Exemestane
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy